Alto Neuroscience, Inc. (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the presentation of data from a randomized, single-blind, placebo-controlled Phase 2a trial of ALTO-207 (formerly CTC-501) in patients with Major Depressive Disorder (MDD). The data were presented in a poster session at the 2026 Annual Meeting of the Society of Biological Psychiatry (SOBP).

ALTO-207 is a fixed-dose combination of pramipexole, a dopamine D3/D2 agonist with antidepressant activity demonstrated across multiple prior studies, and ondansetron, a 5-HT3 antagonist anti-emetic. The novel, patent-protected combination is designed to enable faster titration to higher pramipexole doses by reducing dose-limiting nausea and vomiting — the key barrier that has historically prevented patients from reaching therapeutically effective doses of pramipexole in clinical practice.